2008-2009 Influenza Season Week 17 ending May 2, 2009 by National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division.
 *HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, U.S. Virgin Islands; Region III: DE, DC, 
MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, 
NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and 
Region X: AK, ID, OR, WA) 
 
 
 
2008-2009 Influenza Season 
Week 17 ending May 2, 2009 
All data are preliminary and may change as more reports are received. 
(Due to the response to the novel influenza A (H1N1) investigation, surveillance regions were 
changed from Census Divisions to Department of Health and Human Services (HHS) Regions.) 
 
Synopsis:  During week 17 (April 26 - May 2, 2009), influenza activity increased in the United 
States.   
o One thousand eight hundred ninety-two (13.2%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive 
for influenza. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o No influenza-associated pediatric deaths were reported 
o The proportion of outpatient visits for influenza-like illness (ILI) was 2.6% which is above the 
national baseline. 
o Seven states reported widespread activity, 12 states reported regional activity, the District of 
Columbia and 14 states reported local influenza activity; and Puerto Rico and 17 states 
reported sporadic influenza activity. 
 
 
 
U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.  
 
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  On April 17, 2009, CDC and the California Department of Public Health determined that two 
cases of febrile respiratory illness occurring in children who reside in adjacent counties in southern 
California were caused by infection with a novel influenza A (H1N1) virus. As of May 8, 2009, 1,639 
confirmed infections with novel influenza A (H1N1) infections have been identified by CDC and 
state and local public health departments.  Reporting of novel influenza A (H1N1) viruses by US 
WHO collaborating laboratories began during week 17 and are included in the table below.   
 
During week 17, seasonal influenza A (H1), A (H3), and B viruses co-circulated with novel influenza 
A (H1N1).  The relative proportion of influenza A (H3N2) viruses increased nationally and in six 
(Region I, II, VI, VIII, IX, and X) of the ten surveillance regions*.   
 
The number of specimens tested by WHO and NREVSS collaborating laboratories during week 17 
increased in response to the ongoing novel influenza A (H1N1) virus circulations and investigations.  
The increase in the percentage of specimens testing positive for influenza also may be due in part 
to changes in testing practices by healthcare providers, triaging of specimens by public health 
laboratories, an increase in the number of specimens collected from outbreaks, and other factors. 
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 Week 17 
No. of specimens tested 14,330 
No. of positive specimens (%) 1,892 (13.2%) 
Positive specimens by type/subtype  
Influenza A 1,572 (83.1%) 
        A (H1)         334 (21.3%) 
        A (H3)        300 (19.1%) 
        A (unsubtyped)          308  (19.6%) 
        A (could not be subtyped)                    304 (19.3%) 
        A (novel influenza H1N1)                    326 (20.7%) 
Influenza B 320 (16.9%) 
 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Antiviral Resistance: Since October 1, 2008, 825 seasonal influenza A (H1N1), 132 influenza A 
(H3N2), and 403 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Eight hundred thirty-two influenza A (H1N1) and 141 
influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine and 
rimantadine).  Sixty-eight novel influenza A (H1N1) viruses have been tested for resistance to the 
neuraminidase inhibitors (oseltamivir and zanamivir).  Ninety-six novel influenza A (H1N1) viruses 
have been tested for resistance to the adamantanes (amantadine and rimantadine).  The results of 
antiviral resistance testing performed on these viruses are summarized in the table below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 825 820 (99.4%) 0 (0) 832 4 (0.5%) 
Influenza A (H3N2) 132 0 (0) 0 (0) 141 141 (100%) 
Influenza B 403 0 (0) 0 (0) N/A* N/A* 
Novel Influenza A  
(H1N1) 68 0 (0) 0 (0) 96 96 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
 
Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with 
confirmed, probable or suspected cases of novel influenza A (H1N1) virus infection who are 
hospitalized or who are at higher risk for seasonal influenza complications.  The novel influenza A 
(H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and 
oseltamivir.  It is resistant to the adamantane antiviral medications, amantadine and 
rimantadine. Additional information on antiviral recommendations for treatment and 
chemoprophylaxis of novel influenza A (H1N1) infection is available at 
http://www.cdc.gov/h1n1flu/recommendations.htm 
 
In areas that continue to have seasonal influenza activity, especially those with circulation of 
oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use 
either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide 
adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human 
influenza A (H1N1) virus infection. 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 17, 7.0% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is 
below to the epidemic threshold of 7.5% for week 17. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
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Influenza-Associated Pediatric Mortality:  No influenza-associated pediatric deaths were 
reported to CDC during week 17.  Since September 28, 2008, CDC has received 56 reports of 
influenza-associated pediatric deaths that occurred during the current season.   
 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2005-06 season to present 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).  These two systems 
provide updates of surveillance data every two weeks. 
 
During October 12, 2008 to May 2, 2009, the preliminary laboratory-confirmed influenza-associated 
hospitalization rate for children 0-4 years old in the NVSN was 3.8 per 10,000. Because of case 
identification methods utilized in this study, there is a delay from the date of hospitalization to the 
date of report. 
 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During October 1, 2008 – May 2, 2009, preliminary laboratory-confirmed influenza-associated 
hospitalization rates reported by the EIP for children aged 0-4 years and 5-17 years were 3.5 per 
10,000 and 0.6 per 10,000, respectively.  For adults aged 18-49 years, 50-64 years, and ≥ 65 
years, the rates were 0.4 per 10,000, 0.5 per 10,000, and 1.3 per 10,000, respectively. 
 
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates,  
2008-09 and Previous Three Seasons 
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Outpatient Illness Surveillance: Nationwide during week 17, 2.6% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is above the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
 
 
 
On a regional level, the percentage of visits for ILI ranged from 0.5% to 4.1%. Four of the ten 
surveillance regions reported an ILI percentage above their region specific baselines. 
 
 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 17, the following influenza activity was reported: 
? Widespread influenza activity was reported by seven states (Alabama, Arizona, California, 
Delaware, New Mexico, South Carolina, and Virginia). 
? Regional influenza activity was reported by 12 states (Alaska, Colorado, Florida, Georgia, 
Hawaii, Indiana, Maine, Massachusetts, Nevada, New Hampshire, New Jersey, and Texas). 
? Local influenza activity was reported by the District of Columbia and 14 states (Connecticut, 
Idaho, Iowa, Kansas, Michigan, Montana, New York, North Carolina, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Washington, and Wyoming). 
? Sporadic activity was reported by Puerto Rico and 17 states (Arkansas, Illinois, Kentucky, 
Louisiana, Maryland, Minnesota, Mississippi, Missouri, Nebraska, North Dakota, Ohio, South 
Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin).   
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: May 11, 2009. 
